MiNK Therapeutics Inc. Common Stock (INKT)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

MiNK Therapeutics is a clinical-stage biotech with 15 employees, no reported revenue, and a pipeline centered on agenT-797. That means I cannot judge it by earnings power or assets; I must judge by cash burn and the probability of scientific success. The filed figures show a business not yet commercial: net loss was $3.1M in fiscal Q2 2026, $2.7M in fiscal Q1 2026, $2.9M in fiscal Q3 2025, and $4.2M in fiscal Q2 2025. For full years, net loss was $12.5M in FY2025, $10.8M in FY2024, and $22.5M in FY2023. Diluted EPS was -$0.62 in fiscal Q2 2026, -$0.57 in fiscal Q1 2026, -$0.65 in fiscal Q3 2025, and -$1.06 in fiscal Q2 2025; FY2025 diluted EPS was -$2.93, FY2024 -$2.86, and FY2023 -$6.54. FairStock calculations show poor financial health: trailing free cash flow is -$6.8M, FCF yield is -13.1%, Piotroski is 0/9, Altman Z is -22.13, and ROCE is -123.84%. At the close on 2026-10-13, price was $10.23 and market cap was $52.2M, while FairStock's P/E is -4.28 and EPS is -$2.39. A negative P/E means there are no earnings to value. The FairStock Score is 16/100 and the Peter Lynch category is none because of losses in each of the last four years. The competitive moat is unproven; intellectual property and clinical data could matter, but there is no revenue or profit history. Growth, if it comes, will depend on trial outcomes and financing, not on current earnings. As Graham might say, this is speculation unless one can underwrite the science and the balance sheet. The price reflects hope, not demonstrated value.

In plain English: MiNK Therapeutics is a tiny clinical-stage biotechnology company with 15 employees. It is trying to develop off-the-shelf cell therapies for cancer and immune diseases, but it has no reported revenue and has been losing money. The business looks weak today, and at $10.23 on 2026-10-13 the stock does not look cheap based on its current losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer